Spero pivots to I&I via $1.1B deal with Innovent antibody
Spero pivots to I&I via $1.1B deal with Innovent antibody
Innovent Biologics
Chinese biotech developing innovative biologics including monoclonal antibodies and bispecifics for oncology, ophthalmology, and autoimmune diseases.
Company Info
Upcoming Milestones & Key Dates
2026 H2
Regulatory decision
FDA decision on sintilimab (lung cancer)
2027 H1
Clinical readout
Phase 3 readout for IBI306
Clinical Development Pipeline
Tyvyt (sintilimab)
Target: PD-1 monoclonal antibodyIBI306
Target: PCSK9 monoclonal antibodyIBI344
Target: KRAS G12C inhibitorRecent News
Spero bets up to $1.1B for Innovent’s autoimmune antibody
Spero Therapeutics is putting over $1 billion on the line in exchange for rights to develop SP001, an anti-CD40L antibody, for IgG4-related disease. A Phase 2 study is planned for the second quarter of 2027.
Inside Pfizer's $10B deal with Innovent: a 5-month sprint
Fierce Biotech details the rapid-fire negotiations behind Pfizer's $10 billion deal with Innovent Biologics.
Leadership Team
Michael Yu (Yu Dechao)
Chief Executive Officer
Careers & Job Openings